SHP2 inhibition reduces somatotroph tumor growth in a pre-clinical model
We have demonstrated that SHP2 is more expressed in somatotroph tumors, with its pharmacological inhibition resulting in a reduction of both in vitro and in vivo cell proliferation via STAT3 phosphorylation, making this phosphatase a novel clinical target with promising effects on somatotroph tumors.
Authors
- Jorge Humberto Mukdsi (ORCID: https://orcid.org/0000-0003-2178-6842)
- Florencia Picech (ORCID: https://orcid.org/0000-0002-2783-4270)
- Patricia Calafat
- F Barberá
- Natacha Zlocowski (ORCID: https://orcid.org/0000-0003-0268-9342)
- Erica Faure
- Liliana del Valle Sosa (ORCID: https://orcid.org/0000-0002-3036-8530)
- Juan Carlos De Battista
- Laura Anahí Cecenarro
- Juan Pablo Petiti (ORCID: https://orcid.org/0000-0002-8555-3426)
- Gilda Florencia Mezger
Institutions
- Universidad Nacional de Córdoba (AR)
- Columbia University Irving Medical Center (US)
- Instituto de Investigaciones en Ciencias de la Salud (AR)
- Hospital Privado (AR)
- Columbia University (US)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1093/neuonc/noaf057
- Citations
- 2
- Primary Topic
- Protein Tyrosine Phosphatases
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- Consejo Nacional de Investigaciones Científicas y Técnicas
- Agencia Nacional de Promoción Científica y Tecnológica